Diuretics in the management of chronic heart failure: when and how.

Heart failure is an increasingly prevalent condition resulting in recurrent hospitalisations and significant mortality and morbidity. The management of heart failure has evolved, and multiple drugs have an established mortality benefit in heart failure with reduced ejection fraction. Although the focus should be on ensuring that patients are treated with the maximum tolerated doses of these guideline-directed therapies, diuretics continue to play a key role in the management of clinical congestion in all forms of heart failure. Clinicians play a key role in heart failure management. Familiarity with the role of diuretics and their dosing and monitoring is critical.

Assessing the Generalizability of a Deep Learning-based Automated Atrial Fibrillation Algorithm.

Automated detection of atrial fibrillation (AF) from electrocardiogram (ECG) traces remains a challenging task and is crucial for telemonitoring of patients after stroke. This study aimed to quantify the generalizability of a deep learning (DL)-based automated ECG classification algorithm. We first developed a novel hybrid DL (HDL) model using the PhysioNet/CinC Challenge 2017 (CinC2017) dataset (publicly available) that can classify the ECG recordings as one of four classes: normal sinus rhythm (NSR), AF, other rhythms (OR), and too noisy (TN) recordings. The (pre)trained HDL was then used to classify 636 ECG samples collected by our research team using a handheld ECG device, CONTEC PM10 Portable ECG Monitor, from 102 (age: 68 ± 15 years, 74 male) outpatients of the Eastern Heart Clinic and inpatients in the Cardiology ward of Prince of Wales Hospital, Sydney, Australia. The proposed HDL model achieved average test F1-score of 0.892 for NSR, AF, and OR, relative to the reference values, on the CinC2017 dataset. The HDL model also achieved an average F1-score of 0.722 (AF: 0.905, NSR: 0.791, OR: 0.471 and TN: 0.342) on the dataset created by our research team. After retraining the HDL model on this dataset using a 5-fold cross validation method, the average F1-score increased to 0.961. We finally conclude that the generalizability of the HDL-based algorithm developed for AF detection from short-term single-lead ECG traces is acceptable. However, the accuracy of the pre-trained DL model was significantly improved by retraining the model parameters on the new dataset of ECG traces.

Nondominant Right Coronary Artery Occlusion: Small Vessel, Dramatic Sequelae.

Nondominant right coronary artery (NDRCA) occlusion is rare and generally affects a small volume of myocardium. Despite this, NDRCA occlusion can result in dramatic clinical sequelae. These cases demonstrate the characteristic electrocardiographic findings and consequences of NDRCA occlusion, highlighting the importance of recognition of this pathologic condition to institute appropriate management. (Level of Difficulty: Intermediate.).

A Smartphone-Based Model of Care to Support Patients With Cardiac Disease Transitioning From Hospital to the Community (TeleClinical Care): Pilot Randomized Controlled Trial.

BACKGROUND: Patients hospitalized with acute coronary syndrome (ACS) or heart failure (HF) are frequently readmitted. This is the first randomized controlled trial of a mobile health intervention that combines telemonitoring and education for inpatients with ACS or HF to prevent readmission. OBJECTIVE: This study aims to investigate the feasibility, efficacy, and cost-effectiveness of a smartphone app-based model of care (TeleClinical Care [TCC]) in patients discharged after ACS or HF admission. METHODS: In this pilot, 2-center randomized controlled trial, TCC was applied at discharge along with usual care to intervention arm participants. Control arm participants received usual care alone. Inclusion criteria were current admission with ACS or HF, ownership of a compatible smartphone, age ≥18 years, and provision of informed consent. The primary end point was the incidence of unplanned 30-day readmissions. Secondary end points included all-cause readmissions, cardiac readmissions, cardiac rehabilitation completion, medication adherence, cost-effectiveness, and user satisfaction. Intervention arm participants received the app and Bluetooth-enabled devices for measuring weight, blood pressure, and physical activity daily plus usual care. The devices automatically transmitted recordings to the patients' smartphones and a central server. Thresholds for blood pressure, heart rate, and weight were determined by the treating cardiologists. Readings outside these thresholds were flagged to a monitoring team, who discussed salient abnormalities with the patients' usual care providers (cardiologists, general practitioners, or HF outreach nurses), who were responsible for further management. The app also provided educational push notifications. Participants were followed up after 6 months. RESULTS: Overall, 164 inpatients were randomized (TCC: 81/164, 49.4%; control: 83/164, 50.6%; mean age 61.5, SD 12.3 years; 130/164, 79.3% men; 128/164, 78% admitted with ACS). There were 11 unplanned 30-day readmissions in both groups (P=.97). Over a mean follow-up of 193 days, the intervention was associated with a significant reduction in unplanned hospital readmissions (21 in TCC vs 41 in the control arm; P=.02), including cardiac readmissions (11 in TCC vs 25 in the control arm; P=.03), and higher rates of cardiac rehabilitation completion (20/51, 39% vs 9/49, 18%; P=.03) and medication adherence (57/76, 75% vs 37/74, 50%; P=.002). The average usability rating for the app was 4.5/5. The intervention cost Aus $6028 (US $4342.26) per cardiac readmission saved. When modeled in a mainstream clinical setting, enrollment of 237 patients was projected to have the same expenditure compared with usual care, and enrollment of 500 patients was projected to save approximately Aus $100,000 (approximately US $70,000) annually. CONCLUSIONS: TCC was feasible and safe for inpatients with either ACS or HF. The incidence of 30-day readmissions was similar; however, long-term benefits were demonstrated, including fewer readmissions over 6 months, improved medication adherence, and improved cardiac rehabilitation completion. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry ACTRN12618001547235; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=375945.